Oragenics, Inc.

Contributing Author

Recent Articles by Oragenics, Inc.

Apr-20	Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury OGEN GlobeNewswire
Apr-13	Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury OGEN +12.95% GlobeNewswire
Mar-25	Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation OGEN -7.34% OGEN GlobeNewswire
Mar-17	ORAGENICS FILES ANNUAL REPORT ON FORM 10-K OGEN GlobeNewswire
Mar-12	ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION OGEN +8.50% GlobeNewswire
Mar-11	ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION OGEN -9.90% GlobeNewswire
Mar-10	Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia OGEN GlobeNewswire
Feb-09	Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy OGEN -5.18% GlobeNewswire
Feb-03	Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program OGEN -7.23% GlobeNewswire
Feb-02	Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care OGEN GlobeNewswire
Jan-14	Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico OGEN GlobeNewswire